Pearce IP joins GBMA: Working with GBMA to enable access to affordable medicines

Pearce IP, an award-winning Australian boutique Intellectual Property firm, specialising in the pharma, biopharma and life sciences industries, has joined Australia’s peak body for affordable medicines, the Generic and Biosimilar Medicines Association (GBMA), at a time of change in medicine access policies.

Pearce IP’s Founder and Chief Executive Officer, Ms Naomi Pearce, said she was committed to supporting the GBMA as it developed policies that further enabled all Australians to access affordable medicines.

“Throughout the last few years, in particular with the pandemic, companies supplying medicines have been challenged and stretched in ways that no one could have foreseen. 
 

Having collaborated with GBMA members for more than two decades, I am proud that Pearce IP is strengthening its support for this sector and the patients it serves, in these challenging times.”

GBMA’s CEO, Ms Marnie Peterson, said Pearce IP has joined as its newest Associate Member, as the sector undergoes significant reform, including implementation of the GBMA’s five-year Strategic Agreement with the Government.

GBMA’s Independent Chair, Professor Jane Halton AO PSM, said the Board and members, all welcomed Pearce IP to the shared mission of ensuring all Australian patients had secured access to safe and affordable medicines, in particular biosimilars.

At a time when the cost of living is hurting many families, Professor Halton said more needed to be done to unlock the health and fiscal benefits of biosimilars to deliver savings and restore balance to an overstretched health budget.

Ms Peterson said that drawing on the trusted insights of members, such as Pearce IP, the GBMA would continue to advocate for medicine access policies that supported healthcare sustainability for the long-term.

“The GBMA looks forward to working with all members to ensure Australian patients can continue to access affordable, high-quality medicines, and support those most in need,” Ms Peterson said.

About Pearce IP

Pearce IP is a boutique firm offering intellectual property specialist lawyers, patent attorneys and trade mark attorneys to the pharmaceutical, biopharmaceutical and life sciences industries.  Pearce IP is the 2021 ‘Intellectual Property Team of the Year’ (Lawyers Weekly Australian Law Awards) and was shortlisted for the same award in 2022.  Pearce IP is ranked in IAM Patent 1000 and Managing IP (MIP) IP Stars, in Australasian Lawyer 5 Star Awards as a ‘5 Star’ firm, and the Legal 500 APAC Guide for Intellectual Property.  Pearce IP leaders are well recognised as leading IP practitioners.

Our leaders have been recognised in virtually every notable IP listing for their legal, patent and trade mark excellence including: IAM Patent 1000, IAM Strategy 300, MIP IP Stars, Doyles Guide, WIPR Leaders, 5 Star IP Lawyers, Women in Law Awards – Partner of the Year, Best Lawyers and Australasian Lawyer 5 Star Awards, Women in Business Law Awards – Patent Lawyer of the Year (Asia Pacific), Most Influential Lawyers (Changemaker), among other awards.

About the GBMA:

The Generic and Biosimilar Medicines Association (GBMA) is the peak representative body of generic and biosimilar medicine suppliers in Australia. Its members ensure that all Australians are offered the highest quality generic and biosimilar medicines in the world whilst providing affordable community health outcomes that benefit all Australians.

Generic Biosimilar Medicines Association – gbma.com.au